Fagron NV

Fagron NV

FAGR · BR · Healthcare / Drug Manufacturers - Specialty & Generic

22.8EUR+0.05 (+0.22%)

Price History

Full chart

Market Stats

Previous Close22.75
Open22.85
Day Range22.8 – 22.85
52-Week Range19.4 – 25.3
Volume1.43K
Market Cap1.65B
P/E (TTM)18.00
Forward P/E13.77
EPS1.25
Dividend Yield1.78%
Beta0.38
50-Day Avg22.3
200-Day Avg22.87

About

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; DiluTab, for Cardiology and Primary care application; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders, such as vitiligo; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort; and Cleoderm, a topical cream used for the compounding of personalized dermatological treatments. It also offers education and professional development of prescribers, hospitals, and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Rafael Padilla
  • Employees4.88K
  • HeadquartersVenecoweg 20A, Nazareth, Belgium, 9810, Belgium
  • Websitehttps://www.fagron.com

Leadership

  • Mr. Rafael PadillaCEO & Executive Director · b. 1978
  • Ms. Karin de JongCFO & Executive Director · b. 1979
  • Ms. Vera BakkerChief Operating Officer · b. 1972
  • Ignacio ArtolaGlobal Head of Investor Relations
  • Kenneth BonnellGlobal Head of Quality

Financials

Income Statement

Line item2004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue283.28M283.25M276.97M304.37M354.51M391.31M424.06M492.33M547.02M386.12M447.06M473.00M421.84M436.93M471.68M534.70M555.97M573.81M683.88M762.99M871.96M952.17M
Cost of Revenue198.71M194.02M186.09M----326.13M358.75M215.03M234.91M253.12M237.41M247.58M263.40M294.68M309.24M326.31M397.72M430.38M476.28M747.45M
Gross Profit84.58M89.22M90.88M304.37M354.51M391.31M424.06M166.20M188.27M171.09M212.15M219.87M184.43M189.36M208.28M240.01M246.73M247.50M286.17M332.61M395.68M204.72M
Operating Income25.87M23.81M20.12M26.44M30.03M30.54M36.02M46.26M58.06M73.91M94.34M-150.34M17.88M74.61M73.47M84.39M88.74M87.44M97.91M108.63M130.70M139.41M
EBITDA30.91M33.21M26.97M37.27M39.81M43.08M49.16M59.64M65.64M72.00M110.17M42.33M49.52M92.39M87.17M108.04M115.50M116.00M135.62M134.12M146.56M183.38M
Net Income13.80M15.06M12.12M16.26M14.90M19.64M22.48M28.14M43.91M-32.10M16.23M-202.33M-20.56M46.66M42.49M55.69M59.60M61.00M69.61M70.55M80.55M91.02M
R&D---------6.91M4.33M1.14M960.00K1.24M1.19M1.35M2.05M2.17M2.30M2.70M3.32M-
Interest Expense5.08M3.52M5.50M8.60M12.55M7.99M6.44M10.45M12.30M14.19M23.98M44.05M37.71M21.34M16.09M15.86M14.30M12.70M16.55M22.98M17.44M32.69M

Balance Sheet

Line item2004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets273.19M272.04M285.46M347.47M417.73M472.16M573.59M680.23M748.89M804.69M973.75M689.38M868.05M594.05M682.77M801.24M752.83M800.42M971.01M1.01B1.08B1.24B
Total Liabilities170.65M189.17M190.58M169.24M232.20M275.81M365.47M459.78M503.51M649.53M816.81M754.15M715.18M409.17M473.06M554.80M495.01M474.95M562.38M539.33M578.16M686.87M
Total Equity102.54M82.87M94.88M178.22M181.56M194.31M205.84M216.67M241.63M151.55M154.63M-67.47M149.79M181.40M205.84M242.03M253.11M320.11M402.65M463.75M501.39M551.61M
Cash5.07M4.71M2.53M27.79M18.50M34.28M51.19M69.85M72.35M128.87M108.55M75.47M74.96M60.77M77.58M106.68M84.25M70.65M125.34M133.01M115.04M184.90M
Total Debt93.76M105.89M105.71M72.92M-153.52M217.28M6.29M305.47M423.70M557.21M599.32M580.99M296.97M329.87M391.53M355.54M335.59M399.38M366.74M386.73M468.23M
Net Debt88.69M101.19M103.17M45.13M-18.50M119.24M166.09M-63.56M233.12M294.83M448.66M523.85M506.03M236.20M252.29M284.85M271.29M264.94M274.04M233.74M271.69M283.33M

Cash Flow

Line item2004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow9.04M34.54M17.57M27.10M27.74M39.50M42.13M72.15M67.74M63.08M101.70M73.31M67.50M84.25M73.28M77.17M92.95M78.42M109.46M107.38M109.89M128.28M
Investing Cash Flow-15.50M-38.15M-13.78M-21.72M-58.54M-32.18M-72.64M-62.35M-84.87M-63.53M-193.78M-46.28M-22.93M-11.74M-54.61M-43.59M-51.30M-31.92M-69.27M-44.76M-69.74M-100.36M
Financing Cash Flow2.16M3.25M-5.95M19.90M21.48M8.45M47.12M10.47M23.83M66.53M64.99M-61.46M171.44M-304.39M1.79M-4.49M-53.11M-61.65M13.85M-57.02M-54.01M46.51M
Capital Expenditure11.39M9.05M7.49M16.17M016.32M19.16M019.48M15.82M20.66M22.05M14.78M10.03M15.69M22.17M18.42M20.73M18.50M38.47M26.23M15.25M
Free Cash Flow-2.35M25.49M10.08M10.93M27.74M23.17M22.97M72.15M48.26M47.26M81.04M51.26M52.73M74.22M57.58M55.00M74.53M57.69M90.96M68.91M83.66M113.03M
Dividends Paid16.66M8.37M--1.83M9.07M10.81M13.18M15.30M18.77M22.20M31.37M7.17M7.17M7.17M8.61M5.77M13.03M14.57M18.27M21.05M26.00M

Earnings

Report DateFeb 7, 2014Aug 5, 2014Feb 6, 2015Aug 4, 2015Feb 5, 2016Aug 5, 2016Oct 12, 2016Feb 7, 2017Aug 4, 2017Oct 12, 2017Feb 7, 2018Apr 12, 2018Aug 3, 2018Oct 11, 2018Feb 7, 2019Apr 12, 2019Aug 5, 2019Oct 11, 2019Feb 13, 2020Apr 14, 2020Aug 6, 2020Oct 13, 2020Feb 11, 2021Apr 13, 2021Aug 5, 2021Oct 13, 2021Feb 10, 2022Apr 14, 2022Aug 4, 2022Oct 13, 2022Feb 9, 2023Apr 13, 2023Aug 3, 2023Oct 13, 2023Feb 15, 2024Apr 10, 2024Aug 1, 2024Oct 10, 2024Mar 6, 2025Apr 10, 2025Jul 31, 2025Dec 16, 2025Dec 31, 2025Apr 9, 2026Feb 11, 2027
EPS Estimate0.000.000.000.000.000.181.690.000.001.870.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.00-0.00-0.000.000.000.000.000.000.000.000.00-0.00-0.00-
EPS Actual0.000.000.000.000.000.000.000.000.290.000.360.000.260.000.600.000.380.000.770.000.440.000.820.000.370.000.840.000.480.000.960.000.000.000.000.000.000.000.550.550.630.000.620.00-
Surprise------100.00%-100.00%---100.00%-----------------------------------
Timing----------------------------Pre-marketPre-marketPre-marketAfter-hoursPre-marketPre-market------After-hours---Pre-market

Key Statistics & Ratios

Market Cap1.65B
Enterprise Value2.10B
Trailing P/E18.00
Forward P/E13.77
PEG Ratio15.84
Price / Sales1.61
Price / Book2.68
EPS1.25
Book Value8.11
Revenue (TTM)1.03B
Gross Profit (TTM)456.62M
EBITDA174.59M
Profit Margin8.92%
Operating Margin13.72%
Return on Equity16.70%
Return on Assets6.98%
Shares Outstanding73.39M
Shares Float65.85M
Beta0.38
Dividend Yield1.78%
Dividend Rate0.4
Payout Ratio64.41%

Dividends

20261×
0.40May 18, 2026
20251×
0.35May 19, 2025
20241×
0.30May 21, 2024
20231×
0.25May 15, 2023
20221×
0.20May 16, 2022
20211×
0.18May 17, 2021
20201×
0.08May 14, 2020
20191×
0.12May 16, 2019
20181×
0.10May 18, 2018
20151×
0.93May 14, 2015
20141×
0.67May 14, 2014
20131×
0.56May 15, 2013
20121×
0.46May 16, 2012
20111×
0.41May 11, 2011
20101×
0.33May 12, 2010
20091×
0.28May 13, 2009
20081×
0.06May 15, 2008

Stock Splits

  • Jun 17, 20161202:1117